Skip to content
Peptide research

Livagen

Category
Bioregulators
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic tetrapeptide marketed as a liver bioregulator that enters liver cells and acts on chromatin to support detox and repair. The case rests almost entirely on mechanism and animal data; claims of pain relief and digestive benefits are speculative, with essentially no human trials. No toxicology or pharmacokinetic data exist, and safety data trace mostly to one research group. Not an approved drug in the US; supply is unregulated research material.

Read Full record

Studied uses & evidence

Studied uses(4)

  • Chromatin remodeling and epigenetic rejuvenation

    Low

    Consistent in cultured blood cells from older donors, but never tested in living people.

  • Hepatoprotection and liver function restoration

    Speculative

    Based on animal and cell studies only; no human liver trials exist for this peptide.

  • Enkephalin preservation (endogenous pain modulation support)

    Speculative

    Single lab test showed enzyme inhibition in serum; no pain or mood studies done.

Evidence limits

Evidence Level
Preclinical only

All evidence comes from in vitro human cell studies and animal models. No controlled human clinical trials have been conducted or registered. Research originates almost exclusively from Khavinson's group in Russia and Georgia, with no independent Western replication.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No formal toxicology studies meeting international regulatory standards (ICH guidelines) have been conducted.

    High
  • Sustained chromatin decondensation could theoretically increase chromosomal instability or aneuploidy risk — this has not been investigated.

    Theoretical
  • No pharmacokinetic data exist (absorption, distribution, metabolism, elimination are all unknown in humans).

    Moderate
  • No reproductive or developmental toxicity assessments have been performed.

    Moderate
  • All safety data originate exclusively from the Khavinson research network with no independent Western verification.

    High
  • Human oral bioavailability is unknown; laboratory findings suggest resistance to intestinal peptide hydrolysis.

    Moderate
  • No drug interaction studies have been conducted.

    Moderate
  • Long-term effects of repeated administration are unknown.

    Moderate
  • Commercial products may vary in purity and composition; no standardized pharmaceutical quality controls apply.

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.